Sandoz and Mylan announced the launch of Rosuvastatin Calcium Tablets, the generic version of AstraZeneca‘s Crestor

Crestor is indicated as adjunct to diet and exercise to treat various hyperlipoproteinemias in adults. It is also indicated to reduce risk of MI, stroke, or arterial revascularization procedures in patients without clinically evident CHD but with an increased risk of CVD based on certain factors. In pediatric patients, it is indicated to reduce total-C, LDL-C, and ApoB in heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. 

Related Articles

Rosuvastatin is an HMG-CoA reductase inhibitor that exerts lipid-modifying effects in two ways: it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.

Both Sandoz’s and Mylan’s Rosuvastatin Calcium Tablets are available as 5mg, 10mg, 20mg, and 40mg strengths.  

For more information visit or